Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other 1Endocrine 1CNS 1

Conditions

Pituitary Diseases 1Obesity 1Neoplasms 1Hypoglycemia 1Hyperinsulinism 1Gastro-enteropancreatic neuroendocrine tumor 1Craniopharyngioma 1

Interventions

Everolimus 6Sunitinib 4Octreotide 4Leucovorin 4dabrafenib 3Fluorouracil 33-Iodobenzylguanidine 3trametinib 2selpercatinib 2lutetium Lu 177 dotatate 2avelumab 2alectinib 2PM 01183 2Oxaliplatin 2Irinotecan 2Fulvestrant 2Drug Therapy 2Doxorubicin 2Cisplatin 2trifluridine tipiracil drug combination 1tipifarnib 1telotristat ethyl 1surufatinib 1somapacitan 1ribociclib 1repotrectinib 1pralsetinib 1pentetreotide 1pegfilgrastim 1pasireotide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms × Diazoxide × Endocrine × Clear all
NCT00306683 2011-02-18

Effect of Diazoxide on the Obesity Secondary to Hypothalamic-pituitary Lesions

Assistance Publique - Hôpitaux de Paris

Phase 3 Completed
40 enrolled
CNSEndocrineOther

Craniopharyngioma, Hyperinsulinism, Neoplasms, Obesity, Pituitary Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡